Catalent expands development and analytical capabilities in Swindon, UK
Completes new laboratory suite for the storage and testing of controlled and cytotoxic substances
Catalent Pharma Solutions has completed new laboratories for drug development and analytical testing at its facility in Swindon, UK.
From this suite, the firm will offer analytical testing, development support and regulatory services to pharmaceutical and biopharmaceutical companies.
The laboratory suite incorporates expanded facilities for the storage and testing of controlled and cytotoxic substances. It will offer development and analytical services, including European import testing, Qualified Person (QP) and regulatory consulting services, methods development, and microbial, sterility and stability testing for advanced dose forms including for inhaled and orally administered substances.
‘This additional capacity, coupled with our international network, means Catalent can offer an unparalleled range and scale of services to the development and testing of large and small molecules,’ said Graeme Lowe, Director of Analytical Solutions for Catalent in Swindon.
Lowe added that the enhanced facilities are complemented by Catalent’s acquisitions of Aptuit’s Clinical Trials Supply business and full ownership of the Eberbach softgel facility.
‘We are now offering a broader range of pharmaceutical and biopharmaceutical testing services from five locations in the US, UK and Germany. We have the expertise and the global reach to help our customers bring more products to market faster,’ said Christine Dolan, vp and general manager of Catalent’s Development and Analytical Solutions.
